FREE Daily Stock Alerts From Stock-PR.com
Isilon Systems, Inc. (Nasdaq:ISLN)
ISLN announced its financial results for the quarter endedSeptember 30, 2010. Gross margin for the third quarter of 2010 was 63.5%, Net income for the third quarter of 2010 was $4.0 million, or $0.05 per diluted share, cash flows generated from operations in the third quarter of 2010 were $13.1 million.
Isilon Systems, Inc. designs, develops, and markets network attached storage systems for storing and managing file-based data, including video, audio, digital images, computer models, PDF files, scanned images, reference information, test and simulation data, and other file-based information, as well as other unstructured data worldwide. Its products include Isilon IQ Platform Nodes that supports gigabit Ethernet interfaces for intra-cluster communication and provides front-side communication; Isilon IQ Accelerator-x, which enables customers to increase the performance, or aggregate write and read throughput of their data storage system.
Oracle Corp. (Nasdaq:ORCL)
ORCL announced on October 20, 2010 that Gartner, Inc. has recognized Oracle as a leader in its recent 2010 "Magic Quadrant for User Provisioning." According to Gartner, leaders in user provisioning "are high-momentum vendors (based on sales, world presence and mind share growth), and they have evident track records in user provisioning across most, if not all, market segments. Business investments position them well for the future. Leaders demonstrate balanced progress and effort in the Execution and Vision categories. Their actions raise the competitive bar for all products in the market. They can and often do change the course of the industry.
Oracle Corporation, an enterprise software company, develops, manufactures, markets, distributes, and services database and middleware software, applications software, and hardware systems worldwide. It engages in licensing database and middleware software, including database, application server and application grid, SOA suite and business process management, data migration and integration, business intelligence, identity and access management, content management, portal and user interaction, developer tools, Oracle enterprise manager, and Java platform.
Cavium Networks, Inc. (Nasdaq:CAVM)
CAVM a leading provider of semiconductor products that enable intelligent processing for networking and wireless applications, announced on October 19, 2010 market-leading hardware and software solutions for 4G networks that are being demonstrated at the 4G World 2010 conference at Chicago's McCormick Place. These solutions have been developed in conjunction with major partners including Kontron and Tata Elxsi, and have been optimized for Cavium's OCTEON multi-core MIPS64 processors. The OCTEON wireless processors have been widely adopted in 3G, WiMAX and LTE infrastructure equipment including LTE Base Stations (eNodeBs) and Evolved Packet Core (EPC) devices, 3G Base stations, Cell Site Aggregators, Radio Network Controllers (RNC), xGSNs, Femtocells, Femto Gateways, WiMax base stations and ASN Gateways.
Cavium Networks, Inc. designs, develops, and markets semiconductor processors for intelligent and secure networks. Its semiconductor products enable customers to develop networking, wireless, storage, and electronic equipment that are application-aware and content-aware, and securely process voice, video, and data traffic at high speeds.
Power3 Medical Products, Inc. (PWRM.OB)
Power3 Medical Products, Inc. strives to become the premier biotechnology company specializing in the commercialization of proteomics IP for the diagnosis and treatment of disease by using cutting edge technologies, world class quality procedures and superior research methodologies. PWRM will be guided in all of its dealings with its customers, partners, shareholders, associates and investors by the philosophy of best practices.
PWRM has recently filed several patent applications that are currently pending for its NuroPro technology. PWRM also has a world-wide exclusive license from the Baylor College of Medicine in Houston, Texas. To date, PWRM has given 9 presentations on NuroPro at international scientific meetings in the United States, Europe and China. PWRM has also published 6 articles on NuroPro in peer-reviewed scientific journals. PWRM intends to publish these latest findings as well.
PWRM, a bio-technology company, engages in the development and marketing of diagnostic tests in the fields of cancer, and neurodegenerative and neuromuscular diseases in the United States. PWRM’s products include BC-SeraPro, a proteomic blood serum test for the early detection of breast cancer; and NuroPro, a serum test for the detection of neurodegenerative diseases, such as amyotrophic lateral sclerosis, Alzheimer’s disease, and Parkinson’s disease. PWRM’s products analyze proteins and their mutations to assess an individual’s risk for developing disease later in life or a patient’s likelihood of responding to a particular drug; assess a patient’s risk of disease progression and disease recurrence; and measure a patient’s exposure to drug therapy. PWRM was formerly known as Surgical Safety Products, Inc. and changed its name to Power3 Medical Products, Inc. in September 2003. PWRM was founded in 1992 and is based in The Woodlands, Texas.
To learn more about PWRM visit: http://www.Power3Medical.com
MELA Sciences, Inc. (NASDAQ:MELA)
MELA recently announced that the results of the company's MelaFind pivotal trial and pilot reader study have been published in the online edition of the journal Archives of Dermatology. The paper will appear in the February 2011 print edition of the journal.
MELA Sciences is a medical technology company focused on developing MelaFind. MelaFind is a non-invasive and objective multi-spectral computer vision system designed to aid physicians in the detection of early melanoma from among clinically atypical (those having one or more clinical or historical characteristics of melanoma, such as asymmetry, border irregularity, color variegation, diameter greater than 6 millimeters, evolving, patient concern, regression, and ugly duckling) cutaneous pigmented lesions that are non-ulcerated, not bleeding, and less than 2.2 centimeters in diameter, when a physician chooses to obtain additional information before making a final decision to biopsy to rule out melanoma.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Stock-PR.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold Stock-PR.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://stock-pr.com/disclaimer).Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received 1,000,000 shares 144 restricted stocks for IT department services from Power 3 Medical Products Inc. (PWRM.OB).
Sign Up For Free Stock Alerts At http://stock-pr.com/signup
Be Sure To Visit stock-pr.ning.com
The views expressed in any article, reports, writings are not necessarily the views of Crown Equity Holdings Inc. its officers, directors, staff, contractors or employees. They do not represent the views or opinions of this site. Views expressed in articles are those of the author alone.